Talphera (NASDAQ:TLPH – Get Free Report) posted its earnings results on Monday. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.14, Zacks reports.
Talphera Stock Performance
NASDAQ:TLPH opened at $0.50 on Tuesday. The stock has a 50-day simple moving average of $0.61 and a 200 day simple moving average of $0.71. Talphera has a one year low of $0.45 and a one year high of $1.27. The company has a market capitalization of $8.43 million, a price-to-earnings ratio of -0.72 and a beta of 0.20.
Analysts Set New Price Targets
A number of analysts have recently issued reports on TLPH shares. RODMAN&RENSHAW upgraded shares of Talphera to a “strong-buy” rating in a research note on Tuesday, January 28th. Rodman & Renshaw initiated coverage on Talphera in a report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Talphera in a research note on Tuesday.
About Talphera
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
Read More
- Five stocks we like better than Talphera
- Profitably Trade Stocks at 52-Week Highs
- Amprius Market Gets Amped Up on Growth Outlook
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- ETFs With the Best Returns of 2025: Gold and Silver Miners on Top
- 5 discounted opportunities for dividend growth investors
- Paychex and Cintas Show Surprising Labor Market Resilience
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
